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Background: The mutant prevention concentration (MPC) is an important parameter to evaluate the likelihood of
growth of fluoroquinolone-resistant mutants for antimicrobial-pathogen combinations. The MPCs of
fluoroquinolones for different canine pathogens have not been compared. In this study, we compared for the first
time orbifloxacin MPCs between susceptible strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus
pseudintermedius of canine origin.
Methods: More than 1010 CFU/ml of 10 strains of each bacterial species were inoculated onto Muller-Hinton agar
supplemented with different concentrations of orbifloxacin from 1× to 64× minimum inhibitory concentration (MIC)
and the MPCs were recorded. MICs of original strains and of mutants arising after exposure to sub-MPC
concentrations (one per original strain) were determined in the presence or absence of efflux pump inhibitors
(EPIs). The effects of quinolone resistance-determining region (QRDR) mutations were also examined.
Results: MPCs were significantly higher for P. aeruginosa (16–128 μg/ml) than for E. coli (0.5–32 μg/ml). MPCs for
S. pseudintermedius varied between the low-susceptible (16–128 μg/ml) and the high-susceptible strains (4–16 μg/ml)
and were the most broadly distributed among the three species. Regarding resistance mechanisms, only one QRDR
mutation in gyrA was found in all of the 10 mutants of E. coli and in 4 of the 10 mutants of P. aeruginosa, whereas
mutations in both grlA and gyrA were found in 3 mutants and one mutation in grlA was found in 2 mutants among
the 10 mutants of S. pseudintermedius. In the presence of an EPI, the MICs of P. aeruginosa mutants decreased markedly,
those of E. coli mutants decreased moderately, and those of S. pseudintermedius mutants were unaffected.
Conclusions: MPCs of orbifloxacin vary between bacterial species of canine pathogens, possibly due to the diversity of
the main fluoroquinolone resistance mechanism among these species. Therefore, the type of bacterial species should
be taken into consideration when using fluoroquinolone drugs such as orbifloxacin in canines.
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The incidence of canine pathogens showing decreased
susceptibility or increased resistance to fluoroquinolones
was reported in Japan [1-3] as well as worldwide. Deter-
mination of the mutant prevention concentration (MPC),
the antimicrobial concentration that prevents selection of
resistant mutants, is important for reduction of the inci-
dence of fluoroquinolone resistance [4]. It is hypothesised
that drug exposure below the MPC may promote selection
of resistant strains and the concentration range between the
minimum inhibitory concentration (MIC) and MPC, which
is referred to as the mutant selection window (MSW), may
enrich and amplify resistant mutants. Thus, MPC and
MSW are important parameters for evaluation of the
potential for emergence of fluoroquinolone-resistant
mutants for antimicrobial-pathogen combinations [4].
MPCs of fluoroquinolone in canines have been sporad-
ically reported for single pathogens [5-7]. However, a
consistent comparison of fluoroquinolone MPCs among
different pathogens has not been performed.
Resistance to fluoroquinolone is mediated primarily through
mutations in the quinolone resistance-determining region
(QRDR) of DNA gyrase and topoisomerase IV [8]. Decreased
drug uptake due to overexpression of drug efflux pumps also
contributes to development of fluoroquinolone resistance [8].
Orbifloxacin is a fluoroquinolone that was developed
for use in veterinary medicine and has achieved a rela-
tively large sales volume (approximately 137 kg in 2011)
among fluoroquinolones for companion animals in Japan
[9]. This antimicrobial agent exhibits bactericidal activity
against numerous Gram-negative and Gram-positive bac-
teria (e.g. Escherichia coli, Pseudomonas aeruginosa, and
Staphylococcus pseudintermedius) and is thus indicated
for treatment of canine bacterial infections, including
urinary, skin, and ear infections. Gebru et al. [6,7] found
that orbifloxacin MPCs were relatively high compared to
those of other veterinary fluoroquinolones, which may be
helpful in establishing a comprehensive understanding of
the variation of MPCs among different pathogens.
The purpose of the present study is to investigate dif-
ferences in the likelihood of emergence of fluoroquinolone-
resistant mutants among major bacterial pathogens based
on MPC determination and to characterize the resist-
ance mechanism of mutants. We compared the MPCs of
orbifloxacin among fluoroquinolone-susceptible E. coli, P.
aeruginosa, and S. pseudintermedius strains. Mutants arising
after exposure to sub-MPC concentrations were screened
for QRDR mutations and the effects of efflux pump inhibi-
tors (EPIs) on the MICs of orbifloxacin were determined.
Methods
Bacterial isolates
Ten fluoroquinolone-susceptible strains each of the fol-
lowing three bacterial species were used in this study:E. coli (strains E1–E10), P. aeruginosa (strains P1–P10),
and S. pseudintermedius (strains S1–S10). E. coli and
P. aeruginosa strains were selected from our collection
of urine and ear/skin samples, respectively, obtained from
domestic dogs [1,2]. S. pseudintermedius strains were
isolated from swabs obtained from dogs with canine
pyoderma at the Veterinary Medical Teaching Hospital,
Nippon Veterinary and Life Sciences University, and at
three veterinary hospitals located in Tokyo, Japan. Swabs
were streaked onto mannitol salt agar (Eiken Chemical,
Japan) and typical colonies were collected. Bacterial identi-
fication was carried out by Gram staining, catalase and
coagulase tests, and multiplex-polymerase chain reaction
(PCR) [10]. All confirmed S. pseudintermedius isolates were
stored at −80°C in 10% skimmed milk.
Determination of MPCs and mutant recovery
MPCs were determined using a previously described
protocol [11] with slight modifications. A concentrated
cellular suspension of each bacterial strain (200 μl)
containing >1010 colony-forming units (CFU)/ml was
plated onto each of three Mueller-Hinton agar (Becton
Dickinson, France) plates, which were supplemented
with orbifloxacin at a concentration equal to the MIC
and six doubling dilutions higher than the MIC (i.e. 2×,
4×, 8×, 16×, 32×, and 64× MIC). Plates were incubated
at 37°C for 5 days because preliminary tests showed no
significant differences in MPCs between incubations
for 2 and 5 days, similarly with the previous report
[11]. The lowest drug concentration that prevented
the emergence of mutants after the 5-day incubation
period was recorded as the MPC. Each experiment
was performed twice.
A mutant of each original strain (EM1–EM10, PM1–
PM10, and SM1–SM10) was randomly selected from
plates with a concentration of orbifloxacin that was one
dilution (i.e. twofold) lower than the MPC (sub-MPC).
Each mutant was cultured on antimicrobial-free agar
plates for three serial passages and then stored at −80°C
until further analysis.
Susceptibility testing for orbifloxacin
MICs of orbifloxacin against the original strains and mu-
tants were determined using the agar dilution method,
according to the guidelines of the Clinical and Laboratory
Standards Institute (CLSI) [12]. MICs of orbifloxacin
were also determined in the presence of EPIs: 80 μg/ml
of Phe-Arg-β-naphthylamide (PAβN, Sigma-Aldrich, MO,
USA) for E. coli and P. aeruginosa, and 20 μg/ml reserpine
(Sigma-Aldrich) for S. pseudintermedius. All inoculated
agar plates were incubated at 35°C for 16–20 h. E. coli
ATCC 25922, P. aeruginosa ATCC27853, S. aureus
ATCC29213, and Enterococcus faecalis ATCC29212 were
used as quality control strains.
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The QRDRs of the gyrA and parC genes for E. coli
and P. aeruginosa or of the grlA and gyrA genes for
S. pseudintermedius in the original strains and in repre-
sentative mutants of each original strain were amplified
by PCR using previously described primers [13-15].
The amplicons were bidirectionally sequenced using
the PCR primers.
Statistical analysis
One-way analysis of variance (ANOVA) was used to
compare MPCs and MPC/MIC, serum maximum con-
centration (Cmax)/MPC, and area under the concentra-
tion time-curve (AUC)/MPC ratios among the three
bacterial species, based on the results for ten original
isolates per species. A Tukey test was used to evaluate
differences among the geometric means of these param-
eters. A Welch test was used for pairwise comparison of
MICs. The threshold for significance was set at a value
of P < 0.05 in all analyses.
Results
MICs of original strains and mutants in the presence or
absence of EPIs
The results of the study are summarised in Table 1. The
MICs of orbifloxacin against the original strains and mu-
tants were 0.063–2 μg/ml and 1–8 μg/ml, respectively,
for E. coli, and 1–4 μg/ml and 16–128 μg/ml, respectively,
for P. aeruginosa. Thus, the orbifloxacin MICs against the
original strains of P. aeruginosa were significantly increased
by drug exposure compared with those of the E. coli ori-
ginal strains (4- to 32-fold vs. 2- to 16-fold, P < 0.05).
For S. pseudintermedius, the MICs of orbifloxacin
against the original strains were 0.25–1 μg/ml. After
drug exposure, the MICs of the high-susceptible strains
(S1–S6) increased 1- to 4-fold, whereas those of the low-
susceptible strains (S7–S10) increased 8- to 64-fold. The
MICs of orbifloxacin against the mutants of this species
were widely distributed (0.5–64 μg/ml).
Addition of PAβN, an EPI, resulted in a decrease in
the MICs of orbifloxacin against the mutants and ori-
ginal strains of E. coli and P. aeruginosa (P < 0.05) by 8-
to 32-fold and 32- to 512-fold, respectively. In contrast,
the MICs of orbifloxacin against the original strains
and mutants of S. pseudintermedius were unaffected by
addition of reserpine (P > 0.05). By comparison of the
MICs of mutants for all three bacterial species, the de-
crease in the MIC of orbifloxacin against P. aeruginosa
was more pronounced, compared with those for E. coli
and S. pseudintermedius (P < 0.05).
QRDR mutations in original strains and mutants
Sequence analysis of QRDRs revealed that four low-
susceptible original strains (E7–E10; MIC: 0.5–2 μg/ml)and all the mutants of E. coli harboured one point mutation
(Ser-83→ Leu or Asp-87→Asn) in gyrA. In P. aeruginosa,
four strains (PM4, PM7–PM9) harboured one point muta-
tion (Thr-83→ Ile). No mutations were found in the parC
gene of E. coli or P. aeruginosa.
In S. pseudintermedius, four low-susceptible original
strains (S7–S10; MIC: 1 μg/ml) and four mutants (SM6–
SM10) harboured one point mutation (i.e. Ser-80→ Ile)
in grlA. Of these mutants, three high-level resistant mu-
tants (strains SM7, SM8, and SM10) harboured an add-
itional mutation (i.e. Ser84→ Trp or Leu) in gyrA.
Some original strains (i.e. E10, S2 and S5) gave atypical
mutants without significant increases in MICs and an
additional QRDR mutation emerged after drug exposure,
indicating that these original strains have lower inci-
dence of mutations.
MPCs and MPC/MIC ratios
The MPCs and MPC/MIC ratios for the original strains
of E. coli were 0.5–32 μg/ml and 4–32, respectively. In
this species, low-susceptible strains with one QRDR
mutation (strains E7–E10) had relatively higher MPCs
(8–32 μg/ml), compared with high-susceptible strains
(0.5–2 μg/ml). P. aeruginosa exhibited similar MPCs
(16–128 μg/ml) and MPC/MIC ratios (16–64) for all
original strains. In S. pseudintermedius, the MPCs
(16–128 μg/ml) and MPC/MIC ratios (16–128) in low-
susceptible strains (S7–S10) with one QRDR mutation
were higher than those in high-susceptible strains with-
out QRDR mutations (S1–S6; MPC: 2–8 μg/ml and
MPC/MIC: 4–16).
According to the published pharmacokinetic data of
orbifloxacin, the Cmax and AUC of orbifloxacin at a dose
of 7.5 mg/kg are 6.9 mg/l and 42.9 mg.h/l, respectively,
were obtained [16]. Using these data, the Cmax/MPC
and AUC/MPC ratios were calculated for E. coli, P.
aeruginosa, and S. pseudintermedius as 0.22–13.8
(Cmax/MPC) and 1.34–85.8 (AUC/MPC), 0.05–0.43 and
0.34–2.68, and 0.05–3.45 and 0.34–21.45, respectively. A
comparison among the bacterial species showed that
MPC was significantly higher, but the AUC/MPC and
Cmax/MPC ratios were significantly lower, for P. aeruginosa
compared to E. coli (P < 0.05). There were no significant
differences in these values between S. pseudintermedius
and the other two bacterial species. There were also no
significant differences in the MPC/MIC ratios among
the three bacterial species.
Discussion
Since introduction of the concept of the MPC, there
have been numerous reports of MPCs for fluoroquinolones
against Gram-positive and Gram-negative bacteria, but no
comparisons of MPCs of fluoroquinolones against different
bacterial species under the same experimental conditions.
Table 1 MICs and MPCs of orbifloxacin and QRDR mutations in the gyrA, parC, and grlA genes of the original stains and mutants used in the study
Parent strains
and mutantsa




E1 0.063 <0.015 wt wt 1 16 6.9 42.9
E2 0.063 <0.015 wt wt 0.5 8 13.8 85.8
E3 0.063 <0.015 wt wt 1 16 6.9 42.9
E4 0.125 <0.015 wt wt 2 16 3.45 21.45
E5 0.125 <0.015 wt wt 2 16 3.45 21.45
E6 0.25 <0.015 wt wt 1 4 6.9 42.9
E7 0.5 0.063 S83L wt 16 32 0.43 2.68
E8 1 0.063 D87N wt 8 8 0.86 5.36
E9 2 0.125 D87N wt 8 4 0.86 5.36
E10 2 0.125 S83L wt 32 16 0.22 1.34
EM1 (0.5) 1 0.125 S83L wt - -
EM2 (0.25) 1 0.125 S83L wt - -
EM3 (0.5) 1 0.125 S83L wt - -
EM4 (1) 2 0.125 S83L wt - -
EM5 (1) 2 0.25 S83L wt - -
EM6 (0.5) 2 0.125 S83L wt - -
EM7 (8) 4 0.125 S83L wt - -
EM8 (4) 4 0.25 D87N wt - -
EM9 (4) 8 0.25 D87N wt - -
EM10 (16) 4 0.125 S83L wt - -
P. aeruginosa
P1 1 0.015 wt wt 32 32 0.22 1.34
P2 1 0.031 wt wt 16 16 0.43 2.68
P3 1 0.063 wt wt 32 32 0.22 1.34
P4 2 0.125 wt wt 64 32 0.11 0.67
P5 2 0.063 wt wt 32 16 0.22 1.34
P6 2 0.125 wt wt 32 16 0.22 1.34
P7 2 0.031 wt wt 64 16 0.11 0.67
P8 2 0.063 wt wt 128 64 0.05 0.34
P9 4 0.25 wt wt 64 16 0.11 0.67


















Table 1 MICs and MPCs of orbifloxacin and QRDR mutations in the gyrA, parC, and grlA genes of the original stains and mutants used in the study (Continued)
PM1 (16) 32 0.063 wt wt - -
PM2 (8) 16 0.25 wt wt - -
PM3 (16) 16 0.5 wt wt - -
PM4 (32) 32 1 T83I wt - -
PM5 (16) 32 0.25 wt wt - -
PM6 (16) 64 0.125 wt wt - -
PM7 (32) 64 1 T83I wt - -
PM8 (64) 64 0.125 T83I wt - -
PM9 (32) 128 2 T83I wt - -
PM10 (32) 16 0.25 wt wt - -
S. pseudintermedius
S1 0.25 0.25 wt wt 2 8 3.45 21.45
S2 0.25 0.5 wt wt 2 4 3.45 21.45
S3 0.25 0.5 wt wt 8 16 0.86 5.36
S4 0.5 0.5 wt wt 2 8 3.45 21.45
S5 0.5 0.5 wt wt 4 8 1.73 10.73
S6 0.5 0.5 wt wt 4 4 1.73 10.73
S7 1 1 wt S80I 128 128 0.05 0.34
S8 1 1 wt S80I 128 128 0.05 0.34
S9 1 1 wt S80I 64 64 0.11 0.67
S10 1 1 wt S80I 16 16 0.43 2.68
SM1 (1) 1 1 wt wt - -
SM2 (1) 0.5 0.5 wt wt - -
SM3 (4) 1 1 wt wt - -
SM4 (1) 2 1 wt wt - -
SM5 (2) 0.5 0.5 wt wt - -
SM6 (2) 1 2 wt S80I - -
SM7 (64) 64 128 S84W S80I - -
SM8 (64) 64 128 S84L S80I - -
SM9 (32) 8 8 wt S80I - -
SM10 (8) 32 32 S84L S80I - -
a Number in parenthesis indicates the orbifloxacin concentration (μg/ml) supplemented in the agar from which mutants were derived.
b Minimum inhibitory concentrations (MICs) in the presence of efflux pump inhibitors (EPIs).
c parC of E. coli and P. aeruginosa, and grlA of S. pseudintermedius; wt, wild type; S83L, Ser-83→ Leu; D87N, Asp-87→ Asn; T83I, Thr-83→ Ile; S80I, Ser-80→ Ile; S84W, Ser84→ Trp; S84L, Ser84→ Leu.
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fluoroquinolones against canine pathogens, and the
first determination of the MPC of orbifloxacin against
P. aeruginosa.
Our results showed that the MPC of orbifloxacin against
P. aeruginosa is higher than that against E. coli. Pasquali
et al. [11] also found that the MPCs of enrofloxacin and
ciprofloxacin are higher against P. aeruginosa than against
E. coli. Collectively, these results indicate that P. aeruginosa
has a tendency to exhibit higher MPCs for various drugs
compared with E. coli. In contrast, the orbifloxacin MPCs
against S. pseudintermedius did not differ significantly
from those of E. coli and P. aeruginosa. This result may be
explained by the considerable variation in MPCs among
the strains of S. pseudintermedius. Awji et al. [7] also found
that S. pseudintermedius exhibited a wider range of
orbifloxacin MPCs, compared with those for other vet-
erinary fluoroquinolones. Therefore, the variable MPCs
among S. pseudintermedius strains are likely to be due
to the type of bacterial species and the susceptibility of
the pathogen to orbifloxacin.
To examine the basis for the differences in MPCs of
orbifloxacin among the three bacterial species, we deter-
mined the MICs and fluoroquinolone-resistance mecha-
nisms in MPC mutants of each species. In this study,
high-susceptible strains of E. coli lacking a QRDR mu-
tation and low-susceptible strains with one QRDR
mutation were used as original strains. The MICs of
orbifloxacin against all mutants were categorised as
susceptible or intermediate based on the CLSI break-
point criteria for orbifloxacin (MIC ≥8 μg/ml) [12],
except for one strain (strain E9), which exhibited a
MIC of 8 μg/ml. Sequence analysis revealed that all E.
coli mutants harboured only one QRDR mutation in
the gyrA gene, as also found by Gebru et al. [5]. The
two types of gyrA mutations found in the current study
(S83L and D87N) are known to cause elevated fluoro-
quinolone MICs in E. coli [17,18]. Generally, MICs of
fluoroquinolone against E. coli increase in correspondence
to the number of QRDR mutations [19], which is the
primary mechanism for fluoroquinolone resistance [20].
The emergence of only one QRDR mutation in E. coli
in this study may be mainly responsible for the failure
to acquire orbifloxacin resistance. Similarly, several studies
have shown that most E. coli mutants from MPC plates
had one or none of QRDR mutations even when parent
strains with one gyrA mutation were used [5,6,11]. These
findings imply that E. coli rarely acquires two or more
QRDR mutations in MPC experiments performed under
static conditions. In contrast, all strains of P. aeruginosa
exhibited higher orbifloxacin MICs than the CLSI break-
point and the MICs were significantly higher than those
against E. coli. However, a T83I mutation, which elevates
fluoroquinolone MICs [1,13], was detected in fewer mutantsof P. aeruginosa, compared with E. coli, and there were
no differences in MICs between P. aeruginosa mutants
with and without QRDR mutation. These findings sug-
gest that QRDR mutations in P. aeruginosa play an in-
significant role in the increased MICs of orbifloxacin
against the mutants and increased MPC of orbifloxacin.
MICs of orbifloxacin for P. aeruginosa and E. coli
mutants were significantly decreased by addition of an
EPI (PAβN) but the effect of this EPI was greater on
P. aeruginosa strains than on E. coli strains. Pasquali
and Manfreda [11] similarly found that the decreases in
the MICs of enrofloxacin and ciprofloxacin in the pres-
ence of PAβN were more pronounced for P. aeruginosa
than for E. coli. We previously showed that efflux pumps,
rather than QRDR mutations, play an important role
in the development of fluoroquinolone resistance in
P. aeruginosa [1]. Differential expression of efflux pumps
in E. coli and P. aeruginosa is likely to be the main factor
in the variable increases in orbifloxacin MIC values against
mutants of E. coli and P. aeruginosa and in orbifloxacin
MPCs against these two species.
In S. pseudintermedius, unlike E. coli and P. aeruginosa,
orbifloxacin MICs against the mutants and MPCs against
the original strains differed markedly based on the suscep-
tibility of the original strain. Sequence analysis revealed
three types of QRDR mutations at codon 80 of grlA and
codon 84 of gyrA, which are hotspots for mutations that
decrease fluoroquinolone susceptibility in Staphylococcus
spp., including S. pseudintermedius [3,8]. High-susceptible
original strains lacking the QRDR mutation yielded rela-
tively low orbifloxacin MICs for mutants, which resulted
in relatively low MPCs for original strains. In contrast,
low-susceptible strains with one QRDR mutation mostly
exhibited an additional QRDR mutation after drug expos-
ure and yielded relatively high MICs for mutants, which
resulted in relatively high MPCs for original strains. For
S. pseudintermedius, the relationship between fluoro-
quinolone susceptibility of the original strain and the
MPC value of orbifloxacin has not been investigated
previously. Our results imply that fluoroquinolone sus-
ceptibility and the status of QRDR mutations in the ori-
ginal strains can greatly affect the MICs of orbifloxacin
against mutants and MPC values for original strains.
Further studies are needed to explore these findings.
Addition of an EPI did not significantly affect the MICs of
orbifloxacin against S. pseudintermedius mutants, consist-
ent with the results of Awji et al. [7]. These findings sug-
gest that efflux pumps are not responsible for conferring
fluoroquinolone resistance in S. pseudintermedius.
Conversion of in vitro MPCs into clinically useful data
requires use of pharmacokinetic and pharmacodynamic
parameters of a drug. The Cmax/MPC and AUC/MPC ra-
tios are important predictors for prevention of the emer-
gence of resistant bacteria. In this study, we obtained these
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for orbifloxacin in dogs [16] and found that both
Cmax/MPC and AUC/MPC for orbifloxacin were lower
in P. aeruginosa than in E. coli, although the values in
these two species did not differ significantly from those
of S. pseudintermedius. Olofsson et al. [21] suggested
that an AUC/MPC ratio ≥22 is predictive of prevention
of emergence of a fluoroquinolone-resistant mutant. Thus,
our data may imply that appropriate orbifloxacin
AUC/MPC ratios cannot be achieved, especially in low-
susceptible strains of E. coli and S. pseudintermedius, and in
P. aeruginosa strains. However, the orbifloxacin concentra-
tion may be higher at infection sites of these bacteria
(i.e. urine and skin) than in serum [22,23]. Thus, determin-
ation of the in vivo AUC/MPC ratio at each infection site is
required to evaluate the practical likelihood of the emer-
gence of fluoroquinolone-resistant mutants.
Conclusions
In conclusion, the results of this study showed that the
MPCs and MPC/MIC ratios of orbifloxacin against E. coli,
P. aeruginosa, and S. pseudintermedius are mainly deter-
mined by the primary resistance mechanism of each bac-
terial species. Notably, E. coli and P. aeruginosa, which are
representative Gram-negative bacteria frequently encoun-
tered in companion animal medicine, yielded markedly
different MPCs of orbifloxacin. MPCs were also affected
by the susceptibility (high or low) of the original isolate, es-
pecially in S. pseudintermedius. Therefore, the type of bac-
terial species and the fluoroquinolone susceptibility of the
pathogen should be taken into consideration when using
fluoroquinolone drugs such as orbifloxacin in canines.
Competing interests
The authors declare no potential conflicts of interest with respect to the
research, authorship, and publication of this article.
Authors’ contributions
KH designed and TS carried out all the experiments. TS and KH contributed
equally to this study. TS, KH, and YK were involved in preparation of the
manuscript. KH drafted the manuscript. All authors read and approved the
final version of the manuscript.
Received: 3 December 2012 Accepted: 10 February 2013
Published: 1 May 2013
References
1. Harada K, Arima S, Niina A, Kataoka Y, Takahashi T: Characterization of
Pseudomonas aeruginosa isolates from dogs and cats in Japan: current
status of antimicrobial resistance and prevailing resistance mechanisms.
Microbiol Immunol 2012, 56:123–127.
2. Harada K, Niina A, Nakai Y, Kataoka Y, Takahashi T: Prevalence of
antimicrobial resistance in relation to virulence genes and phylogenetic
origins among urogenital Escherichia coli isolates from dogs and cats in
Japan. Am J Vet Res 2012, 73:409–417.
3. Onuma K, Tanabe T, Sato H: Antimicrobial resistance of Staphylococcus
pseudintermedius isolates from healthy dogs and dogs affected with
pyoderma in Japan. Vet Dermatol 2012, 23:17–e5.
4. Blondeau JM: New concepts in antimicrobial susceptibility testing: the
mutant prevention concentration and mutant selection window
approach. Vet Dermatol 2009, 20:383–396.5. Gebru E, Choi MJ, Lee SJ, Damte D, Park SC: Mutant-prevention
concentration and mechanism of resistance in clinical isolates and
enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine
origin. J Med Microbiol 2011, 60:1512–1522.
6. Gebru E, Damte D, Choi MJ, Lee SJ, Kim YH, Park SC: Mutant prevention
concentration and phenotypic and molecular basis of fluoroquinolone
resistance in clinical isolates and in vitro-selected mutants of Escherichia
coli from dogs. Vet Microbiol 2012, 154:384–394.
7. Awji EG, Tassew DD, Lee JS, Lee SJ, Choi MJ, Reza MA, Rhee MH, Kim TH,
Park SC: Comparative mutant prevention concentration and mechanism
of resistance to veterinary fluoroquinolones in Staphylococcus
pseudintermedius. Vet Dermatol 2012, 23:376–380.
8. Piddock LJ: Mechanisms of fluoroquinolone resistance: an update 1994–1998.
Drugs 1999, 58(Suppl 2):11–18.
9. Laboratory NVA: Ministry of Agriculture, Forestry and Fisheries: Sales Amounts
and Sales Volumes (Active Substance) of Antibiotics, Synthetic
Antibacterials. Tokyo, Japan: Antihelmintics and Antiprotozoals; 2011.
10. Sasaki T, Tsubakishita S, Tanaka Y, Sakusabe A, Ohtsuka M, Hirotaki S,
Kawakami T, Fukata T, Hiramatsu K: Multiplex-PCR method for species
identification of coagulase-positive staphylococci. J Clin Microbiol 2010,
48:765–769.
11. Pasquali F, Manfreda G: Mutant prevention concentration of ciprofloxacin
and enrofloxacin against Escherichia coli, Salmonella Typhimurium and
Pseudomonas aeruginosa. Vet Microbiol 2007, 119:304–310.
12. Clinical and Laboratory Standards Institute: Performance Standards for
Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From
Animals; Approved Standard - Third Edition. PA: CLSI document M31-A3
Wayne; 2008.
13. Akasaka T, Tanaka M, Yamaguchi A, Sato K: Type II topoisomerase
mutations in fluoroquinolone-resistant clinical strains of Pseudomonas
aeruginosa isolated in 1998 and 1999: role of target enzyme in
mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother
2001, 45:2263–2268.
14. Lee YJ, Cho JK, Kim KS, Tak RB, Kim AR, Kim JW, Im SK, Kim BH:
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia
coli isolated from chicken. J Microbiol 2005, 43:391–397.
15. Intorre L, Vanni M, Di Bello D, Pretti C, Meucci V, Tognetti R, Soldani G,
Cardini G, Jousson O: Antimicrobial susceptibility and mechanism of
resistance to fluoroquinolones in Staphylococcus intermedius and
Staphylococcus schleiferi. J Vet Pharmacol Ther 2007, 30:464–469.
16. Walker RD: The use of fluoroquinolones for companion animal
antimicrobial therapy. Aust Vet J 2000, 78:84–89.
17. Yoshida H, Bogaki M, Nakamura M, Nakamura S: Quinolone resistance-
determining region in the DNA gyrase gyrA gene of Escherichia coli.
Antimicrob Agents Chemother 1990, 34:1271–1272.
18. Oram M, Fisher LM: 4-Quinolone resistance mutations in the DNA gyrase
of Escherichia coli clinical isolates identified by using the polymerase
chain reaction. Antimicrob Agents Chemother 1991, 35:387–389.
19. Webber M, Piddock LJ: Quinolone resistance in Escherichia coli. Vet Res
2001, 32:275–284.
20. Chang TM, Lu PL, Li HH, Chang CY, Chen TC, Chang LL: Characterization of
fluoroquinolone resistance mechanisms and their correlation with the
degree of resistance to clinically used fluoroquinolones among
Escherichia coli isolates. J Chemother 2007, 19:488–494.
21. Olofsson SK, Marcusson LL: Komp Lindgren P, Hughes D, Cars O: Selection
of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model;
relation between drug exposure and mutant prevention concentration.
J Antimicrob Chemother 2006, 57:1116–1121.
22. Matsumoto S, Takahashi M, Yoshida M, Komatsu T, Kitadai Y, Horii Y, Katae H:
Absorption, distribution and excretion of orbifloxacin in dogs and cats.
J Jap Vet Med Assoc 1997, 50:470–474. in Japanese with English summary.
23. Kay-Mugford PA, Weingarten AJ, Ngoh M, Zolynas R, White A, Katz T,
Simmons R, Varma KJ: Determination of plasma and skin concentrations
of orbifloxacin in dogs with clinically normal skin and dogs with
pyoderma. Vet Ther 2002, 3:402–408.
doi:10.1186/1751-0147-55-37
Cite this article as: Shimizu et al.: Mutant prevention concentration of
orbifloxacin: comparison between Escherichia coli, Pseudomonas
aeruginosa, and Staphylococcus pseudintermedius of canine origin. Acta
Veterinaria Scandinavica 2013 55:37.
